Loading...

Cosmo Pharmaceuticals

SWX:COPN
Snowflake Description

High growth potential and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
COPN
SWX
CHF1B
Market Cap
  1. Home
  2. CH
  3. Pharmaceuticals & Biotech
Company description

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
COPN Share Price and Events
7 Day Returns
0.5%
SWX:COPN
-2.8%
CH Pharmaceuticals
0.7%
CH Market
1 Year Returns
-29.6%
SWX:COPN
11.2%
CH Pharmaceuticals
2.9%
CH Market
COPN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cosmo Pharmaceuticals (COPN) 0.5% 15.7% 6.4% -29.6% -42.5% -21.3%
CH Pharmaceuticals -2.8% -9.2% -4.8% 11.2% 3.4% 3.9%
CH Market 0.7% 1.1% 5.1% 2.9% 12.7% 12.6%
1 Year Return vs Industry and Market
  • COPN underperformed the Pharmaceuticals industry which returned 11.2% over the past year.
  • COPN underperformed the Market in Switzerland which returned 2.9% over the past year.
Price Volatility
COPN
Industry
5yr Volatility vs Market

Value

 Is Cosmo Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cosmo Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cosmo Pharmaceuticals.

SWX:COPN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.5%
Perpetual Growth Rate 10-Year CH Government Bond Rate 3.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:COPN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate 3.3%
Equity Risk Premium S&P Global 7.1%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.729 (1 + (1- 12.5%) (12.94%))
0.873
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.87
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (0.873 * 7.14%)
9.51%

Discounted Cash Flow Calculation for SWX:COPN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cosmo Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

SWX:COPN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 9.51%)
2019 -18.87 Analyst x3 -17.23
2020 26.50 Analyst x2 22.10
2021 87.00 Analyst x1 66.24
2022 192.00 Analyst x1 133.49
2023 335.00 Analyst x1 212.69
2024 465.64 Est @ 39% 269.95
2025 597.32 Est @ 28.28% 316.22
2026 721.43 Est @ 20.78% 348.75
2027 833.45 Est @ 15.53% 367.91
2028 932.23 Est @ 11.85% 375.77
Present value of next 10 years cash flows €2,095.91
SWX:COPN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €932.23 × (1 + 3.28%) ÷ (9.51% – 3.28%)
€15,437.53
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €15,437.53 ÷ (1 + 9.51%)10
€6,222.72
SWX:COPN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €2,095.91 + €6,222.72
€8,318.63
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €8,318.63 / 14.84
€560.72
SWX:COPN Discount to Share Price
Calculation Result
Exchange Rate EUR/CHF
(Reporting currency to currency of SWX:COPN)
1.143
Value per Share
(CHF)
= Value per Share in EUR x Exchange Rate (EUR/CHF)
= €560.72 x 1.143
CHF641.02
Value per share (CHF) From above. CHF641.02
Current discount Discount to share price of CHF94.20
= -1 x (CHF94.20 - CHF641.02) / CHF641.02
85.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Cosmo Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is CHF94.2 vs Future cash flow value of CHF641.02
Current Discount Checks
For Cosmo Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Cosmo Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Cosmo Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cosmo Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cosmo Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:COPN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-1.20
SWX:COPN Share Price ** SWX (2019-04-18) in CHF CHF94.2
SWX:COPN Share Price converted to EUR reporting currency Exchange rate (CHF/ EUR) 0.875 €82.4
Europe Pharmaceuticals Industry PE Ratio Median Figure of 44 Publicly-Listed Pharmaceuticals Companies 21.68x
Switzerland Market PE Ratio Median Figure of 174 Publicly-Listed Companies 18.53x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cosmo Pharmaceuticals.

SWX:COPN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:COPN Share Price ÷ EPS (both in EUR)

= 82.4 ÷ -1.20

-68.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cosmo Pharmaceuticals is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
  • Cosmo Pharmaceuticals is loss making, we can't compare the value of its earnings to the Switzerland market.
Price based on expected Growth
Does Cosmo Pharmaceuticals's expected growth come at a high price?
Raw Data
SWX:COPN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -68.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
66.3%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.78x
Switzerland Market PEG Ratio Median Figure of 122 Publicly-Listed Companies 2.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cosmo Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cosmo Pharmaceuticals's assets?
Raw Data
SWX:COPN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €29.91
SWX:COPN Share Price * SWX (2019-04-18) in CHF CHF94.2
SWX:COPN Share Price converted to EUR reporting currency Exchange rate (CHF/ EUR) 0.875 €82.4
Switzerland Pharmaceuticals Industry PB Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 2.79x
Switzerland Market PB Ratio Median Figure of 210 Publicly-Listed Companies 1.71x
SWX:COPN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:COPN Share Price ÷ Book Value per Share (both in EUR)

= 82.4 ÷ 29.91

2.75x

* Primary Listing of Cosmo Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cosmo Pharmaceuticals is good value based on assets compared to the CH Pharmaceuticals industry average.
X
Value checks
We assess Cosmo Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Cosmo Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cosmo Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
66.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cosmo Pharmaceuticals expected to grow at an attractive rate?
  • Cosmo Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
  • Cosmo Pharmaceuticals's earnings growth is expected to exceed the Switzerland market average.
  • Cosmo Pharmaceuticals's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:COPN Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:COPN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 66.3%
SWX:COPN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 35.8%
Switzerland Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 5%
Switzerland Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 2.2%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 9.5%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:COPN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:COPN Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 426 231 174 3
2022-12-31 270 113 103 4
2021-12-31 176 50 38 5
2020-12-31 119 18 -2 5
2019-12-31 71 -7 -27 5
SWX:COPN Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 67 -10 -18
2018-09-30 70 -11 -20
2018-06-30 72 -13 -23
2018-03-31 70 -11 -28
2017-12-31 68 -9 -32
2017-09-30 68 -6 -18
2017-06-30 69 -2 -4
2017-03-31 69 10 8
2016-12-31 68 22 19
2016-09-30 70 18 18
2016-06-30 72 14 16
2016-03-31 66 -13 132

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cosmo Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Cosmo Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:COPN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Cosmo Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:COPN Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 11.22 17.70 7.00 3.00
2022-12-31 6.77 9.68 4.83 4.00
2021-12-31 2.16 4.48 0.88 4.00
2020-12-31 0.23 1.75 -1.13 4.00
2019-12-31 -1.80 -1.40 -2.12 4.00
SWX:COPN Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -1.20
2018-09-30 -1.36
2018-06-30 -1.53
2018-03-31 -1.86
2017-12-31 -2.19
2017-09-30 -1.23
2017-06-30 -0.25
2017-03-31 0.56
2016-12-31 1.37
2016-09-30 1.26
2016-06-30 1.15
2016-03-31 9.38

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Cosmo Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Cosmo Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cosmo Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cosmo Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cosmo Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cosmo Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cosmo Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cosmo Pharmaceuticals's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Cosmo Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cosmo Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:COPN Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 66.50 -18.01 50.64 10.39
2018-09-30 69.51 -20.49 52.34 9.67
2018-06-30 72.42 -22.97 54.03 8.95
2018-03-31 70.02 -27.71 50.16 9.00
2017-12-31 67.71 -32.45 46.28 9.05
2017-09-30 68.26 -17.99 38.40 8.78
2017-06-30 68.81 -3.53 30.52 8.51
2017-03-31 68.60 7.91 23.09 8.00
2016-12-31 68.39 19.34 15.66 7.49
2016-09-30 70.34 17.80 12.85 10.43
2016-06-30 72.28 16.26 10.04 13.36
2016-03-31 66.46 132.23 16.45 18.22
2015-12-31 60.63 248.19 22.87 23.08
2015-09-30 59.59 241.11 25.74 23.18
2015-06-30 58.55 234.04 28.60 23.27
2015-03-31 69.10 153.68 22.64 21.24
2014-12-31 79.64 73.32 16.67 19.22
2014-09-30 75.78 77.76 13.51 20.11
2014-06-30 71.91 82.20 10.35 21.01
2014-03-31 64.65 75.47 9.02 19.31
2013-12-31 57.39 68.73 7.69 17.60
2013-09-30 51.40 66.35 7.42 14.94
2013-06-30 45.41 63.96 7.15 12.27
2013-03-31 52.51 41.64 6.57 11.59
2012-12-31 59.60 19.32 5.98 10.92
2012-09-30 58.82 21.03 6.09 9.04
2012-06-30 58.05 22.72 6.21 7.16

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cosmo Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cosmo Pharmaceuticals has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cosmo Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cosmo Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cosmo Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cosmo Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cosmo Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cosmo Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cosmo Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cosmo Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cosmo Pharmaceuticals Company Filings, last reported 3 months ago.

SWX:COPN Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 444.85 158.15 349.44
2018-09-30 444.85 158.15 349.44
2018-06-30 456.37 4.26 187.10
2018-03-31 456.37 4.26 187.10
2017-12-31 470.12 4.48 172.70
2017-09-30 470.12 4.48 172.70
2017-06-30 480.71 4.93 177.57
2017-03-31 480.71 4.93 177.57
2016-12-31 415.56 5.31 166.49
2016-09-30 415.56 5.31 166.49
2016-06-30 414.41 7.42 133.54
2016-03-31 414.41 7.42 133.54
2015-12-31 403.65 8.13 116.34
2015-09-30 403.65 8.13 116.34
2015-06-30 391.74 9.96 47.17
2015-03-31 391.74 9.96 47.17
2014-12-31 152.29 10.93 59.46
2014-09-30 152.29 10.93 59.46
2014-06-30 174.40 10.82 53.47
2014-03-31 174.40 10.82 53.47
2013-12-31 220.16 11.75 168.16
2013-09-30 220.16 11.75 168.16
2013-06-30 182.33 12.65 95.15
2013-03-31 182.33 12.65 95.15
2012-12-31 124.60 12.84 27.30
2012-09-30 124.60 12.84 27.30
2012-06-30 108.30 1.78 31.89
  • Cosmo Pharmaceuticals's level of debt (35.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (5.3% vs 35.6% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Cosmo Pharmaceuticals's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Cosmo Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cosmo Pharmaceuticals has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cosmo Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cosmo Pharmaceuticals dividends. Estimated to be 0.54% next year.
If you bought CHF2,000 of Cosmo Pharmaceuticals shares you are expected to receive CHF0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cosmo Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cosmo Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:COPN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 32 Stocks 3.5%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 167 Stocks 3.1%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.3%
Switzerland Bottom 25% Dividend Yield 25th Percentile 1.9%
Switzerland Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:COPN Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 1.30 2.00
2022-12-31 0.73 3.00
2021-12-31 0.52 5.00
2020-12-31 0.30 5.00
2019-12-31 0.00 5.00
SWX:COPN Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-03-29 0.000 0.000
2018-07-26 0.000 0.000
2017-05-26 1.500 1.258
2016-07-29 1.400 0.923
2014-03-27 1.000 0.748

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cosmo Pharmaceuticals has not reported any payouts.
  • Unable to verify if Cosmo Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cosmo Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cosmo Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Cosmo Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Switzerland.
X
Income/ dividend checks
We assess Cosmo Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cosmo Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cosmo Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cosmo Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alessandro Della Chà
COMPENSATION €1,671,169
AGE 55
TENURE AS CEO 5.1 years
CEO Bio

Mr. Alessandro E. Della Chà, LL.M, has been the Chief Executive Officer of Cosmo Pharmaceuticals N.V. (formerly Cosmo Pharmaceuticals S.p.A) since March 27, 2014 and also has been its Executive Director since 2006. Mr. Chà served as a Senior Partner at Studio Legale Edoardo Ricci e Associati, Milan until March 27, 2014. He specialized in company law, mergers and acquisitions. He joined the Studio Legale Edoardo Ricci e Associati in 1988. He served as an Assistant of the Central Director for Corporate Matters of Fininvest Group from 1987 to 1988. He served as the Non-Executive Vice Chairman of Cosmo Pharmaceuticals N.V. He served as a Director of Santarus, Inc. from April 10, 2012 to January 2, 2014. He served as a Director of II.PP.A.B. Milan (ex-ECA), from 1994 to 1998 a charitable institution owning hospitals and specialized in elderly care. He is Lecturer in conferences and seminars held by universities and institutions on commercial and company law issues. Mr. Chà has a Degree in Law from the University of Milan (ITA) and an LL.M. from the University of Leicester (GBR) in European Union Commercial Law.

CEO Compensation
  • Alessandro's compensation has been consistent with company performance over the past year.
  • Alessandro's remuneration is higher than average for companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the Cosmo Pharmaceuticals management team in years:

6.3
Average Tenure
61
Average Age
  • The average tenure for the Cosmo Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mauro Ajani

TITLE
Founder & Chairman
AGE
63
TENURE
13.3 yrs

Alessandro Della Chà

TITLE
CEO & Executive Director
COMPENSATION
€2M
AGE
55
TENURE
5.1 yrs

Giuseppe Cipriano

TITLE
Chief Operating Officer
AGE
61
TENURE
18.3 yrs

Luigi Moro

TITLE
Chief Scientific Officer
AGE
67
TENURE
19.6 yrs

Chris Tanner

TITLE
Head of Transactions Office & Executive Director
COMPENSATION
€781K
AGE
67
TENURE
2.9 yrs

Niall Donnelly

TITLE
Chief Financial Officer
AGE
44
TENURE
2.8 yrs

Davide Malavasi

TITLE
Technical Director
AGE
45
TENURE
7.6 yrs

John Manieri

TITLE
Head of Investor Relations

Blake Boland

TITLE
Chief Sales Officer
AGE
58
TENURE
2.5 yrs

Massimo Pedrani

TITLE
Head of Generics Business Development
AGE
64
Board of Directors Tenure

Average tenure and age of the Cosmo Pharmaceuticals board of directors in years:

10.1
Average Tenure
61
Average Age
  • The average tenure for the Cosmo Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Mauro Ajani

TITLE
Founder & Chairman
AGE
63
TENURE
7 yrs

Alessandro Della Chà

TITLE
CEO & Executive Director
COMPENSATION
€2M
AGE
55
TENURE
13.3 yrs

Chris Tanner

TITLE
Head of Transactions Office & Executive Director
COMPENSATION
€781K
AGE
67
TENURE
13.3 yrs

Dieter Enkelmann

TITLE
Non-Executive Director
COMPENSATION
€156K
AGE
59
TENURE
13.3 yrs

Kevin Donovan

TITLE
Non-Executive Director
COMPENSATION
€140K
AGE
59
TENURE
3.1 yrs

Geert D’Haens

TITLE
Member of Scientific Advisory Board

William Sandborn

TITLE
Member of Scientific Advisory Board

Silvio Danese

TITLE
Member of Scientific Advisory Board

Maria Roncarolo

TITLE
Non-Executive Director
COMPENSATION
€156K
AGE
64
TENURE
7 yrs

Ralf Kiesslich

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess Cosmo Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cosmo Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Should Cosmo Pharmaceuticals N.V. (VTX:COPN) Be Your Next Stock Pick?

(VTX:COPN) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … In the case of COPN, it

Simply Wall St -

Could Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Investor Composition Influence The Stock Price?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Companies that used to be publicly owned tend to have lower insider ownership. … institutions own shares in the company.

Simply Wall St -

Does Cosmo Pharmaceuticals N.V.'s (VTX:COPN) CEO Salary Compare Well With Others?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Alessandro Della Chà's Compensation Compare With Similar Sized Companies. … has a market capitalization of CHF1.3b, and pays its CEO total annual compensation worth €1.7m.

Simply Wall St -

How Much Of Cosmo Pharmaceuticals NV (VTX:COPN) Do Institutions Own?

The big shareholder groups in Cosmo Pharmaceuticals NV (VTX:COPN) have power over the company. … Cosmo Pharmaceuticals isn't enormous, but it's not particularly small either. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Breaking Down Cosmo Pharmaceuticals NV's (VTX:COPN) Ownership Structure

In this article, I will take a quick look at Cosmo Pharmaceuticals NV’s (VTX:COPN) recent ownership structure – an unconventional investing subject, but an important one. … Ownership structure of a company has been found to affect share performance over time. … Therefore, it is beneficial for us to examine COPN's ownership structure in more detail.

Simply Wall St -

You Should Consider Cosmo Pharmaceuticals NV (VTX:COPN) Because Of These Reasons

Cosmo Pharmaceuticals NV (VTX:COPN) is a stock with outstanding fundamental characteristics. … When we build an investment case, we need to look at the stock with a holistic perspective. … In the case of COPN, it

Simply Wall St -

Breaking Down Cosmo Pharmaceuticals NV.'s (VTX:COPN) Ownership Structure

With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Potential investors in COPN should also look at another important group of investors: private companies, with a stake of 45.08%, who are primarily invested because of strategic and capital gain interests. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

Can Cosmo Pharmaceuticals NV. (VTX:COPN) Improve Your Portfolio Returns?

Generally, an investor should consider two types of risk that impact the market value of COPN. … A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … Based on this beta value, COPN appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market.

Simply Wall St -

Should You Buy Cosmo Pharmaceuticals NV. (VTX:COPN)?

Let’s take a look at Cosmo Pharmaceuticals’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. … This means that if you believe the current share price should move towards its intrinsic value over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range again. … Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price.

Simply Wall St -

Where Cosmo Pharmaceuticals NV.'s (VTX:COPN) Earnings Growth Stands Against Its Industry

Today I will examine Cosmo Pharmaceuticals NV.'s (SWX:COPN) latest earnings update (30 June 2017) and compare these figures against its performance over the past couple of years, in addition to how the rest of COPN's industry performed. … View our latest analysis for Cosmo Pharmaceuticals How Did COPN's Recent Performance Stack Up Against Its Past? … For Cosmo Pharmaceuticals, its latest earnings (trailing twelve month) is -€3.53M, which, against the prior year's figure, has turned from positive to negative.

Simply Wall St -

Company Info

Description

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; and Zacol NMX, a nutraceutical product that uses an amended form of the MMX technology in order to deliver butyric acid and inulin directly to the colon. The company also provides Eleview, a submucosal injectable composition for extracting polyps and adenomas; Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous lesion detection during colonoscopies; and Aemcolo, a pharmaceutical product used for the treatment of bacterial infections of the colon, such as traveler’s diarrhea, infectious colitis, clostridium difficile associated disease, and diverticulitis, as well as for treatment of inflammatory bowel diseases and hepatic encephalopathy. In addition, it offers Qolotag, a medical device that enhances the detection of lesions during sigmoidoscopies; Remimazolam, an ultra-short-acting sedative/anesthetic. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Details
Name: Cosmo Pharmaceuticals N.V.
COPN
Exchange: SWX
Founded: 1997
CHF1,397,524,164
14,835,713
Website: http://www.cosmopharma.com
Address: Cosmo Pharmaceuticals N.V.
Riverside II,
Sir John Rogerson’s Quay,
Dublin,
Co. Dublin, 2,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX COPN New Common Shares SIX Swiss Exchange CH CHF 09. Mar 2007
OTCPK CMOP.F New Common Shares Pink Sheets LLC US USD 09. Mar 2007
DB C43 New Common Shares Deutsche Boerse AG DE EUR 09. Mar 2007
LSE 0RGI New Common Shares London Stock Exchange GB CHF 09. Mar 2007
BATS-CHIXE COPNZ New Common Shares BATS 'Chi-X Europe' GB CHF 09. Mar 2007
Number of employees
Current staff
Staff numbers
306
Cosmo Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 21:13
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.